1-94001068-C-T

Variant summary

Our verdict is Uncertain significance. The variant received 1 ACMG points: 7P and 6B. PM1PM5PP2PP3PP5BP4BS1_SupportingBS2

The NM_000350.3(ABCA4):​c.6320G>A​(p.Arg2107His) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00115 in 1,614,112 control chromosomes in the GnomAD database, including 17 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R2107S) has been classified as Likely pathogenic.

Frequency

Genomes: 𝑓 0.0060 ( 8 hom., cov: 32)
Exomes 𝑓: 0.00065 ( 9 hom. )

Consequence

ABCA4
NM_000350.3 missense

Scores

9
6
3

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications P:22U:1O:2

Conservation

PhyloP100: 7.85

Publications

57 publications found
Variant links:
Genes affected
ABCA4 (HGNC:34): (ATP binding cassette subfamily A member 4) The membrane-associated protein encoded by this gene is a member of the superfamily of ATP-binding cassette (ABC) transporters. ABC proteins transport various molecules across extra- and intracellular membranes. ABC genes are divided into seven distinct subfamilies (ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, White). This protein is a member of the ABC1 subfamily. Members of the ABC1 subfamily comprise the only major ABC subfamily found exclusively in multicellular eukaryotes. This protein is a retina-specific ABC transporter with N-retinylidene-PE as a substrate. It is expressed exclusively in retina photoreceptor cells, and the gene product mediates transport of an essental molecule, all-trans-retinal aldehyde (atRAL), across the photoreceptor cell membrane. Mutations in this gene are found in patients diagnosed with Stargardt disease, a form of juvenile-onset macular degeneration. Mutations in this gene are also associated with retinitis pigmentosa-19, cone-rod dystrophy type 3, early-onset severe retinal dystrophy, fundus flavimaculatus, and macular degeneration age-related 2. [provided by RefSeq, Sep 2019]
ABCA4 Gene-Disease associations (from GenCC):
  • ABCA4-related retinopathy
    Inheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
  • cone-rod dystrophy 3
    Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), G2P, Ambry Genetics
  • severe early-childhood-onset retinal dystrophy
    Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Laboratory for Molecular Medicine, Labcorp Genetics (formerly Invitae), Ambry Genetics
  • retinitis pigmentosa 19
    Inheritance: AR Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
  • cone-rod dystrophy
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • retinitis pigmentosa
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • Stargardt disease
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Uncertain_significance. The variant received 1 ACMG points.

PM1
In a hotspot region, there are 10 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 0 benign, 8 uncertain in NM_000350.3
PM5
Other missense variant is known to change same aminoacid residue: Variant chr1-94001069-G-T is described in ClinVar as Conflicting_classifications_of_pathogenicity. ClinVar VariationId is 497254.
PP2
Missense variant in the gene, where a lot of missense mutations are associated with disease in ClinVar. The gene has 578 curated pathogenic missense variants (we use a threshold of 10). The gene has 28 curated benign missense variants. Gene score misZ: -0.65813 (below the threshold of 3.09). Trascript score misZ: 1.3628 (below the threshold of 3.09). GenCC associations: The gene is linked to cone-rod dystrophy 3, retinitis pigmentosa 19, ABCA4-related retinopathy, severe early-childhood-onset retinal dystrophy, cone-rod dystrophy, Stargardt disease, retinitis pigmentosa.
PP3
Multiple lines of computational evidence support a deleterious effect 8: BayesDel_addAF, BayesDel_noAF, Cadd, Dann, Eigen, phyloP100way_vertebrate, REVEL, REVEL [when AlphaMissense, max_spliceai, FATHMM_MKL, MetaRNN, MutationTaster was below the threshold]
PP5
Variant 1-94001068-C-T is Pathogenic according to our data. Variant chr1-94001068-C-T is described in ClinVar as Conflicting_classifications_of_pathogenicity. ClinVar VariationId is 99448.
BP4
Computational evidence support a benign effect (MetaRNN=0.014489025). . Strength limited to SUPPORTING due to the PP5.
BS1
Variant frequency is greater than expected in population afr. GnomAd4 allele frequency = 0.00598 (911/152284) while in subpopulation AFR AF = 0.0208 (865/41574). AF 95% confidence interval is 0.0197. There are 8 homozygotes in GnomAd4. There are 405 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position passed quality control check. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting
BS2
High Homozygotes in GnomAd4 at 8 AR,AD gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
ABCA4NM_000350.3 linkc.6320G>A p.Arg2107His missense_variant Exon 46 of 50 ENST00000370225.4 NP_000341.2 P78363Q6AI28
ABCA4NM_001425324.1 linkc.6098G>A p.Arg2033His missense_variant Exon 45 of 49 NP_001412253.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
ABCA4ENST00000370225.4 linkc.6320G>A p.Arg2107His missense_variant Exon 46 of 50 1 NM_000350.3 ENSP00000359245.3 P78363

Frequencies

GnomAD3 genomes
AF:
0.00598
AC:
910
AN:
152166
Hom.:
9
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0208
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00196
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.000964
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000735
Gnomad OTH
AF:
0.00287
GnomAD2 exomes
AF:
0.00148
AC:
372
AN:
251290
AF XY:
0.00100
show subpopulations
Gnomad AFR exome
AF:
0.0198
Gnomad AMR exome
AF:
0.000434
Gnomad ASJ exome
AF:
0.000695
Gnomad EAS exome
AF:
0.00103
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000704
Gnomad OTH exome
AF:
0.000163
GnomAD4 exome
AF:
0.000645
AC:
943
AN:
1461828
Hom.:
9
Cov.:
33
AF XY:
0.000538
AC XY:
391
AN XY:
727208
show subpopulations
African (AFR)
AF:
0.0206
AC:
690
AN:
33480
American (AMR)
AF:
0.000559
AC:
25
AN:
44724
Ashkenazi Jewish (ASJ)
AF:
0.000497
AC:
13
AN:
26136
East Asian (EAS)
AF:
0.00227
AC:
90
AN:
39700
South Asian (SAS)
AF:
0.0000116
AC:
1
AN:
86258
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
53374
Middle Eastern (MID)
AF:
0.000520
AC:
3
AN:
5764
European-Non Finnish (NFE)
AF:
0.0000567
AC:
63
AN:
1111998
Other (OTH)
AF:
0.000960
AC:
58
AN:
60394
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.465
Heterozygous variant carriers
0
54
108
162
216
270
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
26
52
78
104
130
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00598
AC:
911
AN:
152284
Hom.:
8
Cov.:
32
AF XY:
0.00544
AC XY:
405
AN XY:
74454
show subpopulations
African (AFR)
AF:
0.0208
AC:
865
AN:
41574
American (AMR)
AF:
0.00196
AC:
30
AN:
15304
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3468
East Asian (EAS)
AF:
0.000966
AC:
5
AN:
5174
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4820
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10604
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.0000735
AC:
5
AN:
68022
Other (OTH)
AF:
0.00284
AC:
6
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.497
Heterozygous variant carriers
0
47
94
140
187
234
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
10
20
30
40
50
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00205
Hom.:
8
Bravo
AF:
0.00674
ESP6500AA
AF:
0.0204
AC:
90
ESP6500EA
AF:
0.000116
AC:
1
ExAC
AF:
0.00187
AC:
227
Asia WGS
AF:
0.00260
AC:
9
AN:
3478
EpiCase
AF:
0.000164
EpiControl
AF:
0.0000593

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:22Uncertain:1Other:2
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not provided Pathogenic:5Uncertain:1Other:2
Jan 27, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 2107 of the ABCA4 protein (p.Arg2107His). This variant is present in population databases (rs62642564, gnomAD 2.1%), including at least one homozygous and/or hemizygous individual. This missense change has been observed in individual(s) with Stargardt disease and/or cone dystrophy (PMID: 9781034, 10458172, 19243736, 24011517, 25066811, 25283059, 28118664, 28446513, 28559085, 29925512, 30060493, 32307445, 32619608). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 99448). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt ABCA4 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects ABCA4 function (PMID: 11017087). This variant disrupts the p.Arg2107 amino acid residue in ABCA4. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 11527935, 23755871, 24097981, 29310964, 29925512, 30718709). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. -

Feb 01, 2024
CeGaT Center for Human Genetics Tuebingen
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

ABCA4: PM3:Very Strong, PM1, PM5, PM2:Supporting, PS3:Supporting, BS2 -

Jun 02, 2015
Eurofins Ntd Llc (ga)
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Nov 29, 2023
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The ABCA4 p.Arg2107His variant accounts for up to 20% of pathogenic variants identified in Stargardt disease patients of African descent (Zernant 2014). This variant has also been identified in trans with other pathogenic alleles (selected references: Rozet 1998, Utz 2013, Jiang 2016, and Fujinami 2019). This variant is found in the African population with an allele frequency of 2% (519/ 24,958 alleles, including 4 homozygotes) in the Genome Aggregation Database. Despite its high population frequency and presence of homozygotes in population databases, only a small number of homozygous individuals with Stargardt disease have been reported in the literature suggesting that in the homozygous state this allele may result in a milder phenotype or reduced penetrance (Zernant 2014). Based on available information, this variant is considered to be likely pathogenic. -

Mar 18, 2022
GeneDx
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Additional genotype/phenotype studies are needed to better establish the contribution of R2107H to disease; This variant is associated with the following publications: (PMID: 16123440, 23499370, 25444351, 26780318, 23982839, 28559085, 16917483, 11385708, 19230850, 14709597, 15223829, 25884411, 26214332, 26311262, 19365039, 23882696, 25066811, 24011517, 11384574, 25283059, 25910913, 19243736, 23953153, 9781034, 29555955, 30093795, 29925512, 32845050, 32581362, 22995991, 22025579, 33301772, 33691693, 34426522, 32619608, 33261146, 22264887, 34073554) -

Oct 23, 2020
Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Retina International
Significance:not provided
Review Status:no classification provided
Collection Method:literature only

- -

-
NEI Ophthalmic Genomics Laboratory, National Institutes of Health
Significance:not provided
Review Status:no classification provided
Collection Method:literature only

- -

Severe early-childhood-onset retinal dystrophy Pathogenic:7
-
Ophthalmo-Genetics Lab, Instituto de Oftalmologia Conde de Valenciana
Significance:Likely pathogenic
Review Status:no assertion criteria provided
Collection Method:research

- -

May 28, 2019
Mendelics
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jan 01, 2015
NIHR Bioresource Rare Diseases, University of Cambridge
Significance:Likely pathogenic
Review Status:no assertion criteria provided
Collection Method:research

- -

-
Juno Genomics, Hangzhou Juno Genomics, Inc
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

PP3_Moderate+PM3_VeryStrong+PP4 -

Jan 01, 2016
Institute of Human Genetics, Univ. Regensburg, Univ. Regensburg
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Oct 07, 2024
Genomic Medicine Center of Excellence, King Faisal Specialist Hospital and Research Centre
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Feb 05, 2025
SingHealth Duke-NUS Institute of Precision Medicine
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant is located in a mutational hotspot where >50% of variants are pathogenic (PM1). Other variant at this amino acid residue has been classified as pathogenic(PM5, p.Arg2107Cys). REVEL score is 0.88 (PP3_mod) -

Retinal dystrophy Pathogenic:3
Jan 01, 2022
Institute of Human Genetics, Univ. Regensburg, Univ. Regensburg
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Aug 11, 2019
Blueprint Genetics
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Oct 01, 2023
Dept Of Ophthalmology, Nagoya University
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:research

- -

Stargardt disease Pathogenic:2
Oct 02, 2023
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The p.Arg2107His variant in ABCA4 has been reported in the compound heterozygous state in at least 19 individuals and in the homozygote state in an individual with clinical features of Stargardt disease. The homozygous individual had late-onset disease (Rozet 1998 PMID: 9781034, Utz 2013 PMID: 24011517, Zernant 2014 PMID: 25066811, Stone 2017 PMID: 28559085, Vallim Salles 2018 PMID: 30093795) and accounts for about 1/5 of pathogenic variants identified in affected individuals of African American descent (Zernant 2014 PMID: 25066811). This variant has also been reported by other clinical laboratories in ClinVar (Variation ID 99448) and has been identified in 2.1% (864/41452) of African chromosomes by gnomAD including 9 homozygotes (http://gnomad.broadinstitute.org, v.3.1.2), which is higher than the expected frequency for penetrant disease-causing alleles. However, very few homozygous individuals with Stargardt disease have been reported in the literature suggesting that in the homozygous state, this allele may result in a milder, subclinical phenotype or reduced penetrance. In vitro studies show that this variant showed slightly reduced expression in transfected cells and decreased ATPase activity but were still able to bind and be stimulated by trans-retinal (Curtis 2020 PMID: 32845050), which could be consistent with the milder phenotype observed in homozygotes and the later age of onset of disease. Computational prediction tools and conservation analyses suggest that this variant may impact the protein. In summary, although additional studies are required to fully establish its clinical significance, this variant meets criteria to be classified as likely pathogenic for autosomal recessive Stargardt disease and is expected to cause more severe disease in the compound heterozygote state with a penetrant, more severe pathogenic variant on the other copy of the gene (in trans). ACMG/AMP Criteria applied: PM3_VeryStrong, PP3. -

Apr 09, 2025
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant summary: ABCA4 c.6320G>A (p.Arg2107His) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.0011 in 1614112 control chromosomes in the gnomAD v4 database, predominantly at a frequency of 0.021 within the African or African-American subpopulation in the gnomAD v4 database, including 16 homozygotes. Although the observed variant frequency within African or African-American control individuals in the gnomAD database is approximately 15-fold of the estimated maximal expected allele frequency for a pathogenic variant in ABCA4 causing Stargardt disease, at least one publication reported the variant was present in ~20% of Stargardt patients in a cohort of African descent (e.g. Zernant_2014). c.6320G>A has been reported in the literature in multiple individuals affected with Stargardt Disease including as a homozygous, compound heterozygous, or heterozygous phenotype (e.g. Lee_2022, Zernant_2014) with one publication providing evidence that the variant is associated with later disease onset and milder disease course in individuals of African descent (Zernant_2014). These data indicate that the variant is very likely to be associated with disease. The following publications have been ascertained in the context of this evaluation (PMID: 34874912, 25066811). ClinVar contains an entry for this variant (Variation ID: 99448). Based on the evidence outlined above, the variant was classified as pathogenic. -

ABCA4-related disorder Pathogenic:1
Mar 05, 2024
PreventionGenetics, part of Exact Sciences
Significance:Likely pathogenic
Review Status:no assertion criteria provided
Collection Method:clinical testing

The ABCA4 c.6320G>A variant is predicted to result in the amino acid substitution p.Arg2107His. This variant has been reported many times to be causative for ABCA4-associated retinal disorders (see for example Rozet et al. 1998. PubMed ID: 9781034; Riveiro-Alvarez et al. 2009. PubMed ID: 18977788; Fujinami et al. 2018. PubMed ID: 29925512). This variant has been documented in 2.1% of alleles in individuals of African descent in gnomAD, including multiple homozygous individuals. While this allele frequency is higher than expected for most pathogenic variants, it has been reported that the carrier frequency for late-onset Stargardt disease is particularly high in the general population (Riveiro-Alvarez et al. 2009. PubMed ID: 18977788). Missense prediction programs classify this amino acid change as damaging, and multiple functional studies have confirmed that this variant has a mild hypomorphic effect on the protein (Sun et al. 2000. PubMed ID: 11017087; Curtis et al. 2020. PubMed ID: 32845050). Given the mild effect, the literature suggests that individuals who are homozygous for this variant have a very mild phenotype (Zernant et al. 2014. PubMed ID: 25066811). In summary, we interpret this variant as likely pathogenic. -

Optic atrophy Pathogenic:1
Jan 01, 2022
Institute of Human Genetics, Univ. Regensburg, Univ. Regensburg
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Macular dystrophy Pathogenic:1
Jan 01, 2015
NIHR Bioresource Rare Diseases, University of Cambridge
Significance:Likely pathogenic
Review Status:no assertion criteria provided
Collection Method:research

- -

Retinitis pigmentosa 19 Pathogenic:1
Jan 09, 2024
3billion
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

It is observed in the gnomAD v2.1.1 (https://gnomad.broadinstitute.org) dataset (total allele frequency: 0.203% NA). Predicted Consequence/Location: Missense variant In silico tool predictions suggest damaging effect of the variant on gene or gene product [REVEL: 0.88 (>=0.6, sensitivity 0.68 and specificity 0.92); 3Cnet: 0.75 (>=0.6, sensitivity 0.72 and precision 0.9)]. Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000099448 /PMID: 9781034 /3billion dataset). The variant has been reported to be in trans with a pathogenic variant as either compound heterozygous or homozygous in at least 4 similarly affected unrelated individuals (PMID: 10458172, 25066811, 28446513, 28559085, 32619608, 9781034). Different missense changes at the same codon (p.Arg2107Cys, p.Arg2107Pro) have been reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000635988 /PMID: 11527935, 18977788). Therefore, this variant is classified as Pathogenic according to the recommendation of ACMG/AMP guideline. -

Severe early-childhood-onset retinal dystrophy;C1858806:Cone-rod dystrophy 3;C1866422:Retinitis pigmentosa 19;C3495438:Age related macular degeneration 2 Pathogenic:1
Jan 20, 2024
Fulgent Genetics, Fulgent Genetics
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.33
BayesDel_addAF
Pathogenic
0.19
D
BayesDel_noAF
Pathogenic
0.51
CADD
Pathogenic
29
DANN
Pathogenic
1.0
DEOGEN2
Uncertain
0.46
T;D
Eigen
Pathogenic
0.84
Eigen_PC
Pathogenic
0.87
FATHMM_MKL
Pathogenic
0.99
D
LIST_S2
Pathogenic
0.99
D;D
MetaRNN
Benign
0.014
T;T
MetaSVM
Pathogenic
1.1
D
MutationAssessor
Uncertain
2.2
.;M
PhyloP100
7.8
PrimateAI
Uncertain
0.62
T
PROVEAN
Uncertain
-4.1
.;D
REVEL
Pathogenic
0.88
Sift
Uncertain
0.0010
.;D
Sift4G
Uncertain
0.026
D;D
Polyphen
1.0
.;D
Vest4
0.99
MVP
0.99
MPC
0.52
ClinPred
0.11
T
GERP RS
6.1
Varity_R
0.52
gMVP
0.87
Mutation Taster
=5/95
disease causing (ClinVar)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs62642564; hg19: chr1-94466624; COSMIC: COSV64672059; COSMIC: COSV64672059; API